chimerix_logo.jpg
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 31, 2023 16:01 ET | Chimerix, Inc.
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
May 25, 2023 07:00 ET | Chimerix, Inc.
DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
May 04, 2023 07:00 ET | Chimerix, Inc.
– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 – – Completion of ONC206 Dose Escalation Expected by First Half 2024 – –...
chimerix_logo.jpg
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
April 27, 2023 07:00 ET | Chimerix, Inc.
DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
April 18, 2023 16:01 ET | Chimerix, Inc.
Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients Multiple Preclinical Datasets Support Potential of Imipridone Platform DURHAM,...
chimerix_logo.jpg
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
March 02, 2023 07:00 ET | Chimerix, Inc.
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma...
chimerix_logo.jpg
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
February 28, 2023 16:05 ET | Chimerix, Inc.
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
February 23, 2023 07:00 ET | Chimerix, Inc.
DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 07:00 ET | Chimerix, Inc.
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
December 08, 2022 17:00 ET | Chimerix, Inc.
– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis – ...